Skip to main content
Evidence Snapshot

Vasopressin V1b receptor

CHEMBL1921 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1921
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vasopressin V1b receptor as ChEMBL target CHEMBL1921, mapped to UniProt P47901. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Vasopressin V1b receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1921
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47901
Vasopressin V1b receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Vasopressin V1b receptor matters

As of 2026-09-13

Vasopressin V1b receptor is reviewed as Vasopressin V1b receptor (UniProt P47901); Vasopressin V1b receptor shows clinical signal disease relevance led by anxiety. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 1375 compounds, and 115 assays, with lead potency reaching pChEMBL 10.5.

Disease context
anxiety

Vasopressin V1b receptor shows clinical signal disease relevance led by anxiety. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include NELIVAPTAN.

Start review with anxiety because it currently carries clinical signal support. Linked drugs include NELIVAPTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 1375 compounds, and 115 assays for this target. The dominant activity type is IC50. CHEMBL1779409 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL1779409 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Vasopressin V1b receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P47901, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why anxiety is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1375
Total Compounds
115
Total Assays
7
Approved Drugs
IC50: 645.0, KI: 284.0, EC50: 345.0, KD: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1779409
 10.5 Ki —
No preferred name
CHEMBL1779410
 10.5 Ki —
No preferred name
CHEMBL1779407
 10.4 Ki —
No preferred name
CHEMBL1779406
 10.1 Ki —
No preferred name
CHEMBL5984549
 9.8 IC50 —

Approved Drugs

Structure Compound First Approval
VASOPRESSIN
CHEMBL373742
 2014
ATOSIBAN
CHEMBL382301
 2000
OXYTOCIN
CHEMBL395429
 1980
DESMOPRESSIN
CHEMBL1429
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1921